Neuland to Open $20m Process Development Facility in Hyderabad
Neuland Laboratories will open a dedicated process development lab and integrated kilo lab at its Genome Valley campus in Hyderabad, India.
Neuland, the global contract development and manufacturing organization (CDMO) specializing in complex APIs has invested $20m in a specialist fit-out at the new 135,000 sq. ft. facility that will be operationalized in phases, with full completion expected by October 2026.
Significantly, it has been designed as a purpose-built integrated scale-up laboratory dedicated exclusively to process development. Once completed, the site will take Neuland’s process development team to more than 500 scientists, making it one of the largest scale-up workforce in India.
Unlike many CDMOs, where process development laboratories may also support discovery or other mixed-use workstreams, the new facility has been designed exclusively for process development. It will also integrate non-GMP kilo labs, allowing scientists to evaluate process performance at larger scales without transferring work to separate sites or competing for access to GMP capacity. This enables teams to continue process optimization while generating real-time scale-up data in parallel.
The center will incorporate AI-driven route scouting, parallel synthesis, and Electronic Laboratory Notebooks (ELNs), enabling faster decision-making, reduced cycle times, and seamless data continuity. A centralized analytical wing will house a comprehensive suite of characterization technologies, with the facility also including specialized zones for process engineering, polymorph studies, process safety, and advanced flow chemistry, alongside five peptide labs and three purification labs.
“The new facility is particularly notable for a few reasons. Firstly, we are using a pre-existing building, so the full $20m investment is being directed towards fitting out the facility rather than constructing the shell. Alongside this, the facility has also been set up with equipment that simulates large-scale reactions at small scale. The end goal is to give clients parallel development and earlier manufacturability insight from the outset,” commented Saharsh Davuluri, Vice Chairman and MD at Neuland Labs.
